Dallas, TX -- (SBWire) -- 11/15/2011 --ReportsnReports.com adds GBI Research Research Report “Endpoints – Clinical Trials in CNS Disorders – Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted’’ to its store.

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints- Clinical Trials in Central nervous system Disorders” which provides an insight into different endpoints that are used in central nervous system clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed Central nervous system drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising Central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

Scope
The report details the clinical trial endpoints in central nervous system disorders. The report covers:
Data and analysis on the marketed products and analysis of their efficacy and safety details
Analysis of the five major Central nervous system diseases which include Alzheimer’s disease, Depression, Epilepsy, Parkinson’s disease and Schizophrenia
Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
Company Profiling talks in detail about the companies, which are strong in the market

Reasons to Buy
The report will help business development and marketing executives who are strategizing their product launches to:
Understand the trends in clinical trial endpoints used for central nervous system diseases
Build effective strategies to launch their pipeline products by identifying the right endpoints
Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for central nervous system diseases
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
Develop key strategic initiatives by understanding the key focus areas of leading companies.

About ReportsnReports
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.